• Clean Power Capital Corp., formerly known as Organic Flower Investments Group, is an investment holding company currently focused on investing and financing companies in the renewable energy market
• The company currently has 10 investments in a variety of sectors, including the legal medical and recreational cannabis market
• The company’s primary investment is PowerTap Hydrogen Fueling Corp., a California-based company in the process of developing large, cost-effective hydrogen fueling infrastructure across North America
• The two companies plan to deploy the hydrogen fueling infrastructure at existing truck stops and gas stations across the country, beginning with up to 1,000 stations within the next three to five years
• Hydrogen produced using PowerTap’s proprietary technology is available at an estimated one-third the cost of traditional production methods and can be generated directly at the filling station
• As hydrogen-powered vehicles become increasingly popular due to their reduced emissions, cost efficiency, lower fueling times and longer driving ranges, the hydrogen industry is expected to grow to $140 billion in annual revenue by 2030 and $750 billion by 2050
• Leveraging proprietary technology and an impressive IP portfolio, PowerTap and Clean Power Capital are uniquely positioned to capitalize on the market growth and expansion opportunities in the hydrogen fueling space

Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) is an investment holding company that focuses on investing in and providing early-stage financing to both public and private businesses. Since its original listing with the Canadian Stock Exchange (“CSE”) on January 23, 2019, the company has made investments in a number of different businesses in a variety of industries, including the energy and cannabis sectors. As per the company’s investment policy, its primary goal is to identify and capitalize on high-return investment opportunities presenting the ability to achieve capital appreciation and liquidity. Clean Power Capital continues to be opportunistic in evaluating prospects across the renewable energy, bio-medical, pharmaceutical and naturopathic sectors, both as an investor and as an operator. The company’s main focus at the moment is to identify such opportunities in the renewable energy industry, including wind, solar and geothermal power and hydrogen and fuel cell technologies, as well as in the biomedical, pharmaceutical and naturopathic sectors, which may include medical or recreational cannabis. Clean Power Capital currently has 10 investments in a variety of sectors and successfully held nearly C$120 million in investments during the past fiscal year (https://ibn.fm/8oktZ). It returned capital to its shareholders through the distribution of its interest in AgraFlora Organics International Inc. in May 2020 (https://ibn.fm/FRAvq). Headquartered in Vancouver, British Columbia, Clean Power Capital was formerly named Organic Flower Investments Group Inc. As of November 10, 2020, the company officially changed its name to Clean Power Capital and started trading on the CSE under new ticker symbol ‘MOVE’. PowerTap Acquisition, Hydrogen Fueling Infrastructure Collaboration In alignment with its updated investment policy, a reconstituted investment committee and a revised strategy to reflect its focus on the renewable energy market, Clean Power Capital recently completed the acquisition of a 90 percent equity interest in California-based PowerTap Hydrogen Fueling Corp. Leveraging an impressive portfolio of IP and advanced deployed technologies developed over two decades via substantial investments and partnerships, PowerTap is working on building and expanding a hydrogen filling station network, initially across North America. The company believes that its platform has a significant advantage over other hydrogen fueling stations, because it has a smaller physical footprint and further has the capacity to produce hydrogen fuel on site. As most other hydrogen fueling stations buy hydrogen for storage at higher costs, PowerTap’s model is believed to be exponentially more cost-effective and expandable. Clean Power Capital’s investment and acquisition will allow PowerTap to step up its efforts and begin work on the hydrogen fueling station network in stages, starting with engineering and design, ongoing development of PowerTap’s third generation product and, finally, licensing & permitting and site preparation. Development is expected to begin in Q4 2021 with engineering and design. Overall, the initial portion of the project is expected to cost $17 million, with Clean Power Capital and PowerTap planning to secure government financing and credit, as well as equity, debt and convertible debt offerings, to fund the infrastructure’s development. PowerTap technology is already deployed across multiple hydrogen fueling stations in public and private enterprises spanning California, Maryland, Massachusetts and Texas. The company plans to deploy its hydrogen fueling infrastructure at existing truck stops and gas stations across the country, beginning with up to 1,000 stations within the next three to five years. At the moment, there are roughly 70 active hydrogen fueling stations operational and available to consumers in the United States. Hydrogen Industry Outlook The project is expected to bring significant opportunities for PowerTap and Clean Power Capital on the fast-growing hydrogen market, driven by a worldwide focus on clean energies and environmentally friendly fueling solutions for the transportation industry. Hydrogen-powered vehicles come with tremendous advantages over gas, diesel and even electric vehicles in terms of cost per mile, fueling time and driving range, as well as boasting significantly lower emissions. Well-established vehicle manufacturers such as Hyundai, Toyota, Daimler and Volvo are already including hydrogen-powered cars in their product lineups, and Nikola Motors has announced plans to manufacture hydrogen electric long-haul vehicles. “As an experienced developer of technology in an important area that is finally having its time as a green but also economically compelling energy option, PowerTap is intent on becoming a leading part of the multi-billion dollar hydrogen fueling space,” PowerTap CEO Raghu Kilambi explained in a news release on October 28, 2020 (https://ibn.fm/oaXem). A recent industry report developed by a coalition of major oil and gas, power, automotive, fuel cell and hydrogen companies indicates that the sector is expected to grow to $140 billion a year in revenue by 2030, creating 700,000 jobs in the U.S. alone (https://ibn.fm/UMI5q). According to Fuel Cell and Hydrogen Energy Association President Morry Markowitz, the sector could expand to $750 billion a year in revenue and 3.4 million jobs by 2050. The U.S. is already engaged in the hydrogen economy, having more than half of the global number of fuel cell vehicles and investing hundreds of millions of dollars a year, but the country can greatly expand its global energy leadership by scaling up operations in the hydrogen economy, per the industry report. With the upcoming change in administration in January 2021, the U.S. is expected to renew its commitment to clean energy. Moreover, the U.S. federal government is expected to invest significantly in clean energy and related infrastructure, including hydrogen, according to PowerTap. “As the U.S. federal government has previously invested in the PowerTap technology, we are optimistic that we will have a seat at the table when USA clean energy/hydrogen infrastructure spending initiatives are designed,” Kilambi added. Management Team Joel Dumaresq is the CEO and interim CFO of Clean Power Capital. He is a proven executive with extensive operational and senior management experience in mining, energy and alternative energy, as well as the cannabis and hemp space. Dumaresq began his career in the corporate finance space, having spent 12 years with RBC Dominion Securities. He brings 30 years of experience in the financial sector to the company, has been instrumental in raising over $250 million in venture capital finance, and he has personally managed a number of successful public listings. Brendan Purdy serves as a director of Clean Power Capital. An experienced businessperson who has led five different companies, Purdy brings years of experience in different industries, including cannabis, blockchain and data security, gaming, mining and energy, and finance and law. He received a graduate degree from the University of Ottawa and an undergraduate degree from the University of Western Ontario. Theo van der Linde serves as a director of Clean Power Capital. He is a Chartered Accountant with over 20 years extensive experience in finance, reporting, regulatory requirements, public company administration, equity markets and financing of publicly traded companies. He has served as a CFO & Director for a number of TSX Venture Exchange- and Canadian Securities Exchange-listed companies over the past several years. His industry experience spans the financial services, manufacturing, oil & gas, mining and retail industries. More recently, van der Linde has been involved with future use trends of natural resources, as well as other disruptive technologies. Raghu Kilambi is the CEO and CFO of PowerTap Hydrogen. He is a seasoned investor and entrepreneur with over 25 years of global business experience in public and private investments, building businesses and creating shareholder value. He has raised over $1 billion of equity and debt capital for private and public companies and been involved in many M&A acquisitions and exits. For more information, visit the company’s website at www.CleanPower.Capital. NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF

• Online gaming industry outperformed both box office, record music industries by more than $100 billion in 2019
• The eSports segment expected to rise from $1 billion in 2019 to $1.7 billion in 2021
• Dozens of revenue streams exist within online gaming industry, each presenting an opportunity to capitalize on everchanging market

The online gaming industry is quickly growing into a multibillion-dollar industry. Even though it began in the 1970s, the space did not enter the mainstream until the 1990s when increasing numbers of people had access to the internet. Since then, the industry has rapidly grown into one of the most profitable industries worldwide. In 2019 it outperformed both the global box office and global recorded music industries by more than $100 billion. Esports makes up one segment of this ecosystem, and Mobius Interactive is ready to capitalize on this segment. To help the company achieve that objective, Mobius has strategically unveiled three diverse gaming brands: Aragon Casino, Club Double, and Mobius.Bet. Aragon Casino and Club Double provide access to more than 4,000 live table games, video poker and slots that can be played via desktop or mobile. Mobius.Bet focuses on eSports, offering an estimated 34 unique games and tournaments. Mobius.Bet is Mobius Interactive’s dedicated eSports hub. It caters to the 18- to 38-year-old eSports community with loyalty programs, targeted gamification and product merchandising. The eSports segment is expected to rise from $1 billion in 2019 to $1.7 billion in 2021. Mobius launched as an online gaming operator in September 2020, but it isn’t entering as a new player. The company’s leadership team brings with it a wealth of experience in the gaming world and in creating successful startups. All one has to do is take a look at the top two players to recognize they aren’t new to the game. CEO Lynn Pearce has more than 15 years of success in the global gaming industry, writes regularly for “Infinity Gaming Magazine” and has been a judge for the International Gaming Awards. Robin Lawson, vice president and COO, is one of the original founders of the eSports.com brand and has been involved in iGaming for more than a decade. Esports may only be a fraction of the $196 billion in revenue the online gaming industry is estimated to reach by 2022, but it’s not the only market that Mobius has entered. There are dozens of revenue streams within the online gaming industry, each presenting an opportunity to capitalize on an evergrowing, everchanging market. In partnership with leading and award-winning eSports and iGaming platform Ultra Play, Mobius Interactive seeks to attract a network of high-net-worth gamers from around the world through the use of loyalty and gamification programs designed to enhance engagement by leveraging state-of-the-art customer relationship management systems and joint ventures with more than 600 VIP and master-gaming affiliates. The possibilities of online gaming are endless, and Mobius has already launched an eSports hub, live Casinos, slots and more. Over 4,000 online games are currently available from this company that launched only a few months ago. One can only imagine what new adventures Mobius has waiting for its gamers. For more information, visit the company’s website at www.MobiusInteractive.ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• MustGrow uses novel plant compounds to develop superior and safer alternatives to current synthetic chemicals used as pesticides, fungicides and nematicides
• The company leverages its innovative technology platform and the natural defensive mechanisms of the mustard plant for broad use in crop production and protection in order to provide consumers the healthy, safe and natural foods they demand
• The company has EPA approval for the granule form of its flagship product, TerraMG, and is currently waiting to receive approval for the liquid form in the United States and Canada
• MustGrow already has multiple projects in various stages of development, with a focus on all-natural and organic solutions for crops
• The liquid form of TerraMG has the potential for multiple applications, thus significantly enhancing the company’s IP position
• MustGrow is focused on the disruption of the global pesticide market, which totals $65 billion, while testing multiple applications of TerraMG and other products in significant markets
• The company has 37 million shares outstanding; management and advisors own 22%

MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) is an agricultural biotech company focused on developing and commercializing natural biological solutions for high-value crops, including fruits and vegetables. The company uses novel compounds from the mustard plant to provide superior and safer alternatives to current synthetic chemicals used as pesticides, fungicides and nematicides. Management & advisors own 22% of the company’s 37 million shares outstanding. Leveraging its innovative platform, MustGrow effectively extracts the natural defense mechanisms of the mustard seed for broad use in crop production and protection. The company uses components of mustard seed to provide high quality, organic pest control to growers facing challenges associated with soil-borne diseases and pests like nematodes. This company’s all-natural, effective, safe and easy-to-use solution is ideal for farmers looking to raise healthy crops without chemical pesticides amid growing concerns worldwide over the negative effects of chemical pesticide solutions. MustGrow, which went public in 2019, was founded in Saskatoon, Canada, and is currently focused on disrupting the $65 billion global pesticide market with its 100% owned and patented mustard-derived technology. Canada produces 28% of the global mustard crop and is the world’s largest exporter, with a 57% market share. TerraMG and Pipeline The company’s technology extracts the mustard plant’s natural organic compounds, which, when combined with water, form Allyl isothiocyanate (AITC) and serve as a natural defense mechanism for the plant against pests and diseases. MustGrow’s mustard-derived technology acts as both a natural bio-pesticide and as a non-selective bio-herbicide. There are currently more than 110 independent third-party trials that confirm the safety and efficacy of MustGrow’s solutions, potentially positioning the company as a leading provider of safe plant protection solutions in a market that is gradually eliminating the use of chemical compounds. MustGrow’s primary product at the moment is the new liquid formulation TerraMG, which has the potential to compete against existing chemistries on both efficacy and price. Its initial target market is as a pre-plant soil bio-pesticide for use with higher-value crops such as fruits and vegetables. This liquid formulation is safe and easy to transport and has already demonstrated its efficacy against several pests and diseases. In addition to its use as a pre-plant soil treatment, TerraMG has significant potential for multiple applications in several other markets, which is expected to aggressively expand the company’s IP portfolio. MustGrow has already confirmed or is in the process of testing multiple applications of TerraMG, including fruit and vegetable soil fumigation ($1.2 billion estimated global market), container fumigation ($2 billion estimated global market), tobacco nematode and disease fumigation ($4 billion estimated global loss), non-selective herbicide ($13 billion estimated global market), food-borne pathogens ($15 billion estimated global market) and more. The company anticipates registration approval for the liquid formulation (TerraMG) as a pre-plant bio-pesticide for soil-borne diseases and pests from the EPA (United States) and PMRA (Canada) in 2021. The company already has EPA and PMRA approval for the product’s granular form. Currently, MustGrow’s pipeline also includes:

• TerraMG, a pre-plant soil bio-pesticide, for:
  • Fruit & Vegetable– currently in Phase 4
  • Turf & Ornamental– currently in Phase 4
  • Tobacco– currently in Phase 4
  • Potatoes– currently in Phase 4
  • Canola– targeting Clubroot Disease – currently in Phase 3: Advanced Development/Field Trials
  • Bananas– targeting Fusarium wilt TR4 – currently in Phase 1: Proof of Concept/Laboratory
  • Pulse Crops– targeting Aphanomyces – currently in Phase 1: Proof of Concept/Laboratory
• Non-Selective Bio-Herbicide– targeting noxious or resistant weeds – currently in Phase 2: Early Development/Greenhouse
• Storage Bio-Pesticide for Bulk Grain, Fresh Produce– targeting toxins, diseases and insects – currently in Phase 1: Proof of Concept/Laboratory
• Storage Bio-Pesticide for Shipping Containers– targeting fungus, invasive pests and diseases – currently in Phase 1: Proof of Concept/Laboratory
• Bio-Pesticide for Foodborne Pathogens– targeting E. coli, salmonella, Listeria, human pathogens, etc. – currently in Phase 1: Proof of Concept/Laboratory

Market Opportunity The protection of crops with synthetic chemical pesticides represents a $65 billion-dollar global market that is expected to grow in the coming years as the global population grows and needs more food. This number doesn’t include bio-pesticide sales, which are projected to increase to $8.5 billion by 2025, with a CAGR of 14.7%. MustGrow, with its natural bio-pesticide, is targeting not only the bio-pesticide market, but also the global synthetic chemical market so as to help replace harmful synthetic pesticides and provide a natural biologic that has the efficacy of controlling pests and disease compared to synthetic chemicals in some instances. Management Team Corey Giasson is the President, CEO and Director of MustGrow. He is an entrepreneur focused on the agriculture, mining, real estate and oil/gas industries, primarily in the Canadian province of Saskatchewan. Giasson is co-founder and director of Legacy Capital Corp. This private equity company focuses on participating in management buyouts of strong, sustainable cash flowing businesses. He has an MBA and B.Sc. in Agriculture Economics from the University of Saskatchewan. Colin Bletsky is COO and Director of MustGrow. He grew up in Eastern Saskatchewan on his family’s third-generation farm, growing canola, wheat and oats. The majority of his time is spent helping other organizations and farmers grow their businesses – locally and globally. Bletsky has a Bachelor of Science in Agriculture from the University of Saskatchewan and executive education from the London School of Business and INSEAD. Todd Lahti is the company’s CFO. He has extensive experience evaluating and managing biotech, agricultural and oil/gas start-up companies by working directly on financing transactions, mergers and acquisitions, business development, corporate strategy, technology transfer and operations setup. Lahti is a Chartered Financial Analyst and a Chartered Professional Accountant. Brad Munro is Chairman of MustGrow. He is the President and CEO of Bittercreek Capital Corp., a private investment and advisory firm. He has extensive corporate finance and investment experience in the natural gas and oil industries, among others. Munro has a Bachelor of Commerce from the University of Saskatchewan. NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

• Pure Extracts trading on CSE under “PULL” symbol
• Pure Extracts cannabis and hemp industry verticals include toll processing, white labeling and developing its own private label of cannabis products
• Pure Extracts is entering the functional mushroom market
• Company’s CO2 extraction facility complies with European Union GMP standards – intends to seek EU GMP certification for exports to Europe

Pure Extracts Technologies (CSE: PULL), a plant-based extraction company focused on the cannabis, hemp, and functional mushroom sectors, recently announced that the Company’s stock is now trading on the Canadian Securities Exchange (“CSE”) under the symbol “PULL”. “Our trading debut on the CSE is another vote of confidence in our ability to effectively meet the needs of consumers focused on receiving cannabis, hemp and functional mushroom products,” said Pure Extracts’ Chief Executive Officer Ben Nikolaevsky (https://ibn.fm/wRim3). Mainstream science is starting to prove what users have known for years – that functional mushrooms and cannabis-based products can help treat symptoms associated with a variety of physical and mental conditions. Pure Extracts is ahead of the curve in leveraging the market for plant-based medicines on a global scale through a strategy focused on product development, facility expansion, license procurement and product marketing. “There currently is tremendous consumer demand for natural health products with the ability to immediately enhance our quality of life,” said Nikolaevsky. “With Health Canada officially granting Pure Extracts a Standard Processing License under the Cannabis Act, this has put us on a path to deliver full-spectrum oil products by the end of Q4, 2020.” Interest in plant medicines has increased in the scientific community in recent years, particularly regarding the anti-inflammatory effects associated with cannabis (https://ibn.fm/7g4vs) and the ability of cannabidiol (“CBD”) to relieve chronic pain associated with a variety of conditions (https://ibn.fm/ZRbn6). Accordingly, Pure Extracts engages in three cannabis/hemp-related verticals that include in-house marketing for their own brands, converting raw biomass into marketable products, and providing white labeling services for brands looking to enter the rapidly growing market. Functional mushrooms – another Pure Extracts vertical – are rapidly emerging in the collective awareness for their ability to combat illness, increase mental cognition and improve digestion. Varieties containing psilocybin, also known as “psychedelic” or “magic” mushrooms”, are currently being studied by prestigious research institutions like UC Berkeley as a possible treatment for depression, anxiety, PTSD, bipolar disorder, Alzheimer’s disease and addiction (https://ibn.fm/BNc5a). Therapy options may be available in the near future as FDA approvals for their use in treatment-resistant depression are expected sometime in 2021 (https://ibn.fm/et1aY). If this happens, demand for highly purified, pharma-grade, mushroom extracts has the potential to skyrocket. Based in Pemberton, British Columbia, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act on September 25, 2020. The Company engages in the cannabis and hemp industry through toll processing, white labeling, and developing its own private label products, in addition to expanding its business to include functional mushrooms. The Company has a fully-built CO2 extraction facility that complies with European Union GMP standards and intends to seek EU GMP certification in order to export its products to jurisdictions within Europe where such products are legal. For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Knightscope’s ASRs have completed over one million field hours and are continuing to improve over time based on field experience
• Knightscope designs, engineers, and builds its ASRs in Silicon Valley, continuing to create American jobs in an economy severely impacted by the pandemic
• The company is committed to changing the way public safety and protection are delivered nationwide
• By joining the $39 billion self-storage industry, Knightscope is targeting to become a prominent security provider in the sector, translating into further opportunities for growth

Knightscope, a developer of advanced physical security technologies utilizing fully autonomous robots focused on enhancing U.S. security operations, is committed to helping create peace and maintaining public safety nationwide via the superior technology it develops and deploys. Combining self-driving technology, robotics and artificial intelligence, Knightscope’s Autonomous Security Robots (“ASRs”) provide 24/7/365 security and are currently patrolling five time zones across the United States, assisting in the creation of safer public and private spaces. The company’s ASRs are a means of physical deterrence, patrolling sites autonomously and providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The collected data is available round the clock through the company’s Knightscope Security Operations Center (KSOC), an intuitive interface that also features 360-degree eye-level HD video streaming, facial recognition, people detection, thermal anomaly detection, automatic license plate recognition, and automatic signal detection. In a recent video presentation titled “Knightscope: Peace Through Superior Technology,” CEO William Santana Li explained how Knightscope’s ASRs are changing the way protection is delivered across the United States (https://ibn.fm/dg15A). It is estimated that there are two million police officers and security personnel across the United States for more than 300 million people across the 50 states. Knightscope’s ASRs are helping to bridge the gap, covering more ground with round-the-clock coverage. In addition to patrolling and peacekeeping, the ASRs have already helped law enforcement and security with the arrests of suspects in crimes that range from armed robbery to hit-and-run accidents. More information about the work Knightscope is doing to fight crime is available at www.Knightscope.com/crime. The current ASR product offering from Knightscope currently includes a K1 stationary unit, a K3 indoor machine, and the K5 outdoor machine. Since the K5 outdoor machine’s deployment, the City of Huntington Park Police Department has noted significant changes in their calls for service (down 10%), crime reports (down 46%), arrests (up 27%), and citations (down 68%). The data was compiled from June to December 2018, before deployment, and compared to June to December 2019, after deployment. Since the company’s creation in 2013, several milestones have already been achieved, including:

• Establishing a 15,000-square-foot facility in Mountain View, California, where Knightscope designs, engineers, and builds their proprietary technology;
• Completing more than one million hours in the field, securing contracts across five United States’ time zones; and
• Continuing to hire and navigate the global pandemic without interruptions, despite the current economic and societal disruptions.

Furthering its position in the industry, Knightscope recently signed an agreement with a Southern California storage facility to utilize the company’s ASR technology. Storage units are particularly susceptible to theft and vandalization. Entry into this $39 billion a year industry offers Knightscope tremendous potential for growth (https://ibn.fm/9S9BC). The long-term vision of Knightscope is to keep an eye on the greater good. The company’s mission is to make the United States of America the safest nation, supporting millions of law enforcement and security personnel across the country. For more information, visit the company’s website at www.Knightscope.com.    Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button in the lower right corner (it is not a bot) for direct contact with CEO.  NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• BRSF announce partnership with Dalmore Group
• New product launch presents solution for growing need for rapid EEG testing due to COVID-19 pandemic
• Brain Scientific shose to extend proposed Reg A+ offering to attract additional investors

Brain Scientific (BRSF), a commercial-stage healthcare company providing next-gen solutions to the neurology market, has announced a partnership with the Dalmore Group in a recent press release (https://ibn.fm/clcDx). “We are delighted to get the Dalmore Group on board and to be able to offer our stock to a much wider pool of investors,” said Brain Scientific chairman Boris Goldstein. “Our partners are experienced with Regulation A+ offerings and are licensed in all 50 states.” The Dalmore Group is a member of FINRA and SIPC with an active presence in the Regulation A+ equity funding space. As one of the most active broker-dealers in the world, the company has served as broker-dealer on more than 50 RegA+ offerings in the past 12 months alone. In 2019 the Dalmore Group raised over $1 billion of capital. The majority of Dalmore Group’s clients come by referral from securities attorneys and industry participants. BRSF is looking to the Dalmore Group for its expert strategic advice and innovative solutions. The Dalmore Group prides itself on understanding a client’s critical business processes and financial goals in order to provide the most comprehensive services possible. Brain Scientific recently launched the next-gen, 19-channel NeuroCap(TM) device. This is a hospitable-grade disposable EEG headset that presents a solution for the growing need for rapid EEG testing due to the COVID-19 pandemic. Through the use of a special adapter, the NeuroCap is compatible with any other amplifiers of EEG signals. Two of the biggest challenges of administering EEGs is the need to measure a patient’s head and the time needed to place the electrodes accurately. This required a specialized neurological technician. The pre-gelled fixed electrode locations, in accordance with the International 10-20 System, allow the NeuroCap to be administered by any healthcare worker making it more accessible to a larger group of patients. The ease of use opens the device up for application in hospitals, clinics and rural areas where medical resources may be limited. Also, the global pandemic is still raging, and new studies show more than 80% of hospitalized COVID-19 patients have neurological symptoms, which could require EEG testing (https://ibn.fm/qRf8w). “With our recent product development and new product launches,” said Goldstein, “we feel the need to extend the proposed Regulation A+ Offering to attract additional investors, which we believe we can better accomplish by working with Dalmore.” For more information, visit the company’s website at www.BrainScientific.com. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Globally it is estimated that 70,000 people suffer from CF, with half the population in the United States
• The global CF therapeutics market size was valued at $4.62 billion in 2018 and is expected to reach an estimated $9.3 billion by 2026
• AzurRx BioPharma’s MS1819, currently undergoing clinical trials, is a promising therapy for severe exocrine pancreatic insufficiency in patients with cystic fibrosis

While still a relatively rare genetic disease, cystic fibrosis (“CF”) remains a dangerous condition that affects multiple body functions and organs, putting patients at risk of developing severe life-threatening illnesses. This is why the need for innovative and effective therapies for the treatment of CF-associated ailments, such as AzurRx BioPharma’s (NASDAQ: AZRX) drug candidate for exocrine pancreatic insufficiency, is constantly growing. According to Allied Market Research, the demand for effective treatment options is driving a global expansion of the CF therapeutics market. Further driven by the availability of personalized drug therapy and molecular prosthetics, the global CF therapeutics market is expected to reach $9.3 billion by 2026, from $4.62 billion in 2018 (https://ibn.fm/E8kIz). Cystic fibrosis is a progressive, genetic disease characterized by persistent lung infections and limited breathing ability over time as well as significant digestive problems. It is caused by a mutation of the cystic fibrosis transmembrane conductance regulator (“CFTR”) gene making it unable to transport salts across cell membranes, resulting in the buildup of thick and sticky mucus in different organs and tissues. In the lungs, the mucus clogs the airways and traps germs, which leads to infections, respiratory failure, inflammation, and other complications. The pancreas is also affected by the buildup of mucus, which prevents the release of digestive enzymes. These digestive enzymes are key to absorbing food and nutrients, often leading to malnutrition and poor growth (https://ibn.fm/ucQP4). Many patients with CF have a weak immune system and are also at a higher risk of developing other severe health conditions, such as hypersplenism, diabetes, cirrhosis, osteoporosis and arthritis. Globally, it is estimated that 70,000 people suffer from cystic fibrosis, but the incidence of the disease varies significantly across the globe, as prenatal and newborn screening for CF is not standard practice. The U.S. has one of the highest incidence rates with about 35,000 diagnosed cases, according to the Centers for Disease Control (https://ibn.fm/YBzVq). A World Health Organization report indicates that the incidence of CF in the U.S. is one in every 3,500 births and slightly higher in the European Union, where one in 2,000-3,000 newborns are affected (https://ibn.fm/DEFzu). While the condition is largely underdiagnosed in Africa and Asia, a recent study out of India showed that the prevalence of cystic fibrosis could be higher than previously believed. Research conducted by Sir Ganga Ram hospital in Rajendra Nagar, Delhi, and published in the BMC Medical Genetics of London, indicated that one in 2,000 newborns in the populous Asian nation may be at risk of being born with CF, after finding a high carrier frequency of 4.5% in male and female subjects (https://ibn.fm/fCIZ4). AzurRx’s MS1819 Showing Promising Results Technological advances have greatly increased the lifespan for those suffering from CF, especially since the 1950s when children with CF rarely made it to elementary school age (https://ibn.fm/5m5XR). The median age of survival for a CF patient is now around 47 years, with many patients living into their 60s (https://ibn.fm/66lO7). Due to the efforts of companies such as AzurRx BioPharma, the lifespan and quality of life of CF patients could be further improved. AzurRx’s lead product is MS1819, a recombinant lipase that could potentially change the treatment of exocrine pancreatic insufficiency (“EPI”) in CF and chronic pancreatitis (“CP”) patients. The company is currently undergoing Phase 2 trials and pursuing approval through parallel monotherapy and combination therapy pathways. The two current clinical trials for MS1819 in CF patients are a Phase 2b Option 2 monotherapy trial and a Phase 2 combination therapy trial, using MS1819 together with porcine pancreatic enzyme replacement therapy (“PERT”), the current standard of care. Preliminary results from the combination trial have shown clinically meaningful improvements in subjects, with no adverse safety events. The company believes that due to its safety and efficacy, MS1819 has the potential to improve the quality of life and help achieve healthier nutrition for many patients suffering from severe EPI. AzurRx is scheduled to complete treatment of all patients and announce top line data from both clinical studies in 2021. For additional information, visit www.AzurRx.com or contact the following: AzurRx BioPharma, Inc. Martin Krusin Vice President for Corporate Development Phone: (646) 699-7855 info@azurrx.com NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

• Technical report supports recent positive feasibility study announcement
• Study projects average annual metal production of 136,000 tonnes of copper, 231,000 ounces of gold and million-plus ounces of silver
• Josemaria one of world’s very few readily developable copper-gold projects

Josemaria Resources (TSX: JOSE) (OTC: JOSMF) has filed a key technical report to support its recent positive feasibility study announcement. The report, which was prepared under National Instrument 43-101 Standards for Disclosure for Mineral Projects, is in regard to the company’s wholly owned Josemaria Copper-Gold Project, located in San Juan Province in Argentina. Last month Josemaria Resources announced the positive results of a feasibility study focused on its Argentine property. The study reported a robust, rapid pay-back, low-risk project with an open-pit operation feeding a conventional process plant at 152,000 tonnes a day; the mine life was estimated to last 19 years. The study projected an average annual metal production of 136,000 tonnes of copper, 231,000 ounces of gold and more than a million 1,164,000 ounces of silver. “We are extremely pleased with the results of the Feasibility Study at Josemaria, which indicates that this is one of the very few readily developable copper-gold projects in the world today,” said Josemaria Resources president and CEO Adam Lundin. “This study has materially de-risked the project and forecasts an attractive economic outcome which is comparable with other large-scale copper/gold projects already being developed or in production today. We believe that Josemaria is perfectly positioned to commence production by mid-decade, meeting rising copper demand from a rapidly electrifying global economy. I believe the study results will allow us to unlock various financing opportunities as we move toward construction.” The study was prepared by a team of engineering and consulting service providers led by Fluor Canada Ltd. with key sections prepared by SRK Consulting (Canada) Inc. and Knight Piésold Ltd. The study was conducted in accordance with the disclosure standards of National Instrument 43-101. The feasibility report comes at an ideal time for JOSE. In 2019, the global smart mining market totaled approximately $6.8 billion; current trends indicate it will more than triple that by 2025, reaching approximately $20.31 billion. That increase, experts observe, will be driven by technological advancements within the sector. Another positive indicator for the Josemaria project is the steady growth in demand for both copper and gold. The global copper market is expected to reach $222.1 billion by the end of 2026, while demand for gold is also expected to rise as economic uncertainty increases globally. Josemaria Resources is a Canadian natural resources company based in Vancouver, British Columbia. The company’s current focus is on advancing the development of its wholly owned Josemaria copper-gold mining project. Josemaria Resources is part of the Lundin Group of companies, a conglomerate of 13 business entities operating in the mining, oil and gas and renewables sectors around the world. For more information on Josemaria Resources, visit the company’s website at www.JosemariaResources.com. NOTE TO INVESTORS: The latest news and updates relating to JOSMF are available in the company’s newsroom at https://ibn.fm/JOSMF

• Life sciences technology innovator Pressure BioSciences (OTCQB: PBIO) has increased its IP stable to 26 patents worldwide with the announcement of its first U.S. patent for its revolutionary Ultra Shear Technology(TM) (“UST”) Platform
• The patent (US 10,823,159) – entitled “System for High Pressure, High Shear Processing of Fluids” – will be the framework of the company’s new instrument line (the BaroShear K45 Nanoemulsification System) to be commercially released in mid-2021
• UST is expected to revolutionize the processing of immiscible liquids into high quality, highly profitable nanoemulsions
• Nanoemulsions are highly sought after in a variety of industries because of their ability to improve stability, appearance, taste, and/or water solubility of retail products (e.g., food, beverages, cosmetics) as well as for the delivery and bioavailability of biopharmaceutical drugs and vaccines
• The legal cannabidiol (“CBD”) industry has been particularly attractive to the company because of its nascent and enormous popularity, leading to projections from multiple sources that it will surge to a $47 billion market by 2025
• Pressure BioSciences expects to deliver on the preorder of its first dozen BaroShear K45 Systems during the first half of next year, which is expected to generate additional revenue for the company of about $3 million, and that is just for the first half of 2021

Pressure BioSciences (OTCQB: PBIO) recently announced the issuance of the first U.S. patent for its  innovative Ultra Shear Technology (UST) platform  that utilizes ultra high pressure and intense shearing forces to make unique, high-quality nanoemulsions that have enormous use in a wide variety of industries. The announcement brings PBI’s IP patent portfolio up to 26 worldwide and should move the company rapidly towards significantly increased revenue and profitability. The patent for the company’s trademarked Ultra Shear Technology (“UST”) platform entitled “System for High Pressure, High Shear Processing of Fluids” is the first long-term patent (20-year) for UST in the world, and takes Pressure BioSciences another step closer toward its mid-2021 planned commercial release of the BaroShear K45 System, which will be the company’s first UST-based processing system to reach the market (https://ibn.fm/ozzPZ). The UST platform was created to revolutionize the process of mixing liquids that normally do not mix, such as oil and water, but without the need for high quantities of chemicals that are all too common in today’s nanoemulsions. The chemically emulsified mixtures of these liquids currently have wide use in everyday products, such as foods, pharmaceutical drugs and nutraceuticals, cosmetics, industrial lubricants and most recently cannabis oil extracts that are becoming increasingly popular with legalization.  PBI’s UST processed nanoemulsions are expected to exceed the quality of today’s chemically-produced nanoemulsions, while decreasing the cost of manufacture and minimizing the need for large amounts of added chemicals. Nano particles offer a large surface area in relation to their volume due to their small size, which provides them with special chemical, physical and biological properties in contrast to bulk matter at normal scale (https://ibn.fm/sJn1N). While nano particles are currently used in high-quality items like scratch-proof glasses and transparent sunscreens, their medical applications are perhaps of greatest interest. Drug makers look to nano emulsions as a means of transporting medicines to specifically targeted disease cells, such as cancers, reducing damage to nearby healthy ones. Lipid-based nano particles (“LNP”) are increasingly sought after as vaccine carriers for preventative medical purposes as well.  PBI’s UST nanoemulsification platform offers the potential to quickly and successfully compete in these existing areas, because of its many advantages over current processes. The hemp-derived cannabidiol (“CBD”) market’s pursuit of efficient nanoemulsification for superior delivery, absorption, and bioavailability of its oil-based nutraceuticals is also a potentially very lucrative market because changing perspectives toward cannabis worldwide have created a booming nascent industry. Cannabis market research firm BDS Analytics CEO Roy Bingham predicts legal CBD will become a $47 billion market by 2025 (https://ibn.fm/xZllS). “Nanoemulsions have long been shown to exhibit improved absorption, higher bioavailability, and greater stability, while often requiring lower levels of emulsifiers than macro/micro emulsion products,” Senior Vice President of Engineering Dr. Edmund Y. Ting stated in the company announcement. “Because of these significant advantages, nanoemulsions are currently the focus of numerous research efforts worldwide. However, cost-effective scale-up of high quality nanoemulsion processing at a commercial level continues to be quite challenging. Importantly, we believe that PBI’s innovative and now patented UST platform can provide the key to commercial success for nanoemulsion products.” The company has received pre-orders for 12 BaroShear K45 systems, which it plans to deliver during the first half of 2021 for up to $3 million in additional revenue (https://ibn.fm/TgON9). Pressure BioSciences also is in talks with academic organizations and government agencies that have expressed interest in the UST platform for other product and research possibilities, such as an alternative for processing fresh milk, juices, and other dairy products into a long-term stable, room temperature, tasty products. For more information, visit the company’s website at www.PressureBioSciences.com. NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

• HempFusion Wellness, Inc. is a health and wellness company developing the power of whole-food hemp nutrition through more than 40 products currently on store shelves
• The company is focused on industry safety and quality standards through regulatory compliance, and is currently participating in a real world consumer study to establish the safety of daily cannabidiol (“CBD”) use in regard to liver function
• HempFusion has filed a preliminary prospectus for a planned initial public offering of its stock in Canada and a listing on the Toronto Stock Exchange
• Despite a reduction in hemp farm acreage this year following last year’s glut, market watchers anticipate the industrial hemp market is expected to reach $22 billion by 2022

The U.S. election this month demonstrated the lasting potential of the market for cannabis-derived products when five states joined the march toward legalizing marijuana for recreational or medicinal uses (https://ibn.fm/T6k3q). Despite a variety of challenges that plagued the nascent hemp industry in 2019 as well as the contentious societal debates over the COVID-19 pandemic’s impact on everyday life and the choices for president, cannabis’ hemp and marijuana offshoots seem to have transcended the upheaval that has defined 2020. Denver-based HempFusion Wellness has continued to build its own movement toward market success in the cannabis wellness industry, developing 46 products that are currently on shelves while establishing the second-largest cash position in its sector without debt. And in October the company announced a preliminary prospectus with the securities regulatory authorities in Canada, excepting the Quebec province, for a proposed initial public offering of common shares and listing on the Toronto Stock Exchange that makes HempFusion the first US-based cannabidiol (“CBD”) company to apply to list on the TSX (https://ibn.fm/FuBS6). HempFusion Wellness has invested heavily in regulatory compliance in order to meet and exceed the safety and quality standards established not only by government officials, but selective consumers and retailers as well. As a member of the U.S. Hemp Roundtable, the company works with other coalition members in advancing the safety of hemp and CBD products. The company’s focus on regulatory compliance has in turn opened doors to major food and drug mass market retailers. HempFusion has its eye on five channels — natural health retail outlets, Internet-based commerce, big box chains and other mass markets, doctor / care provider referrals and convenience stores. HempFusion’s proprietary Whole Food Panoramic Full-Spectrum Hemp Complex products present solutions for basic, specific needs such as sleep, energy and stress. Its offerings include tinctures and capsules, as well as FDA listed over-the-counter (“OTC”) products designed to combat pain, eczema, acne and skin aging, and wounds. HempFusion is one of 12 companies working to capture real world evidence from consumers on how they use CBD products and how their bodies react to those products, with a primary focus on whether daily use is safe for the liver in response to questions raised by the U.S. Food and Drug Administration (https://ibn.fm/482lB). “We believe this real world evidence is important to the FDA and could be used to guide policy moving forward,” Patrick McCarthy, the CEO of life sciences researcher ValidCare, which is conducting the scientific study, stated. Licensed hemp farm acreage decreased on a year-over-year basis in 2020 for the first time since the 2014 Farm Bill established a national hemp pilot program, according to industry watchers (https://ibn.fm/IrgQU). The downward movement was driven by regulatory uncertainty and a vast oversupply of hemp last year in the wake of the previous winter’s updating of the 2014 bill to provide broader legalization to hemp as an agricultural commodity. It is important to note, HempFusion is not a cultivator and is instead focused on product R&D, increased distribution and consumer safety. Nevertheless, Brightfield Group has projected the hemp CBD market to reach $22 billion by 2022 (https://ibn.fm/f7eC4). For more information, visit the company’s website at www.HempFusion.com/Corporate-Information. NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/HempFusion